Peptipedia / Research subject

Tirzepatide

Studies of tirzepatide, including GIP/GLP-1 receptor agonism and clinical trial publications.

Explore the papers.

8 publications

2026 AugBrain and behavior
The Neuroprotective Potentials of Dual GIP/GLP1-RA (Tirzepatide): From Preclinical Experiments to Clinical Trials: A Scoping Review.
Hawas Y, Abouzid M, Gadelmawla AF et al.
PubMed · PMID 42608956Scoping Review
2025 May 28Journal of clinical medicine
Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies.
Quarenghi M, Capelli S, Galligani G et al.
PubMed · PMID 40507553Review
2025 Feb 1The Journal of endocrinology
Cardiovascular effects of tirzepatide.
Sumithran P, Russell AW, Zoungas S
PubMed · PMID 39751188Review
2025 JanExpert opinion on pharmacotherapy
Tirzepatide for overweight and obesity management.
Hamza M, Papamargaritis D, Davies MJ
PubMed · PMID 39632534Review
2024 FebDrugs
Tirzepatide: A Review in Type 2 Diabetes.
France NL, Syed YY
PubMed · PMID 38388874Review
2023 JulEuropean journal of internal medicine
Tirzepatide and potential use for metabolically healthy obesity.
Copur S, Tanriover C, Yavuz F et al.
PubMed · PMID 37183081Review
2022 JulDrugs
Tirzepatide: First Approval.
Syed YY
PubMed · PMID 35830001Review
2020 Sep 3JCI insight
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Willard FS, Douros JD, Gabe MB et al.
PubMed · PMID 32730231Journal article